JCO: Sytoxides monotherapy treats advanced head and neck squamous cell carcinoma with the lower efficacy than cisplatin.

Head and neck squamous cell carcinoma (HNSCC) is the seventh most common malignant tumor in the world, with more than 800,000 new cases worldwide each year.
treatment of HNSCC, which is late localized (Phase III-IV), is still challenging.
surgery combined radiotherapy (RT) is the preferred treatment for localized advanced oral cancer and a treatment option for oral, lower and throat cancers.
journal of Clinical Oncology recently published the results of a Phase III ARTSCAN trial comparing radiotherapy with cisplatin vs sytoxides monoantigen therapy for local late-stage HNSCC patients.
ARTSCAN trial was an open-label randomized controlled trial in which subjects (1:1) received RT-Stoic monoantigen (400 mg/m2 week) or RT-cisplatin (40 mg/m2 week).
end point is total survival rate (OS), and the secondary endpoint is local control, local control of dose incremental RT, failure mode and adverse reactions.
was terminated early when 298 patients were randomly grouped after an interim analysis of the study process.
3 years, the OSs in the cisplatin group and the Sytoxi monoantigen group were 88% and 78%, respectively (correction risk ratio 1.63, p=0.086).
the cumulative local failure rates of the overall survival prognostic cisplatin group and the sitoxid monoantigen group were 9% and 23%, respectively.
the cumulative rate of distant metastasis between the two groups of local treatment failure was not significantly different.
dose incremental treatment of stage T3-T4 tumors did not increase the rate of local disease control.
two groups of distant transfers, the study showed that the partial control of partial late-stage HNSCC was not as good as cisplatin combined radiotherapy.
other studies are needed to identify subgroups that may benefit from sitoxidoxy monoantigen therapy.
.